Introduction
Rates of HIV acquisition and progression, and levels of viral control during the clinical latency period, show differences between individuals, which are in part due to genetic variation (Shea et al., 2013) . The role of gene copy number variation (CNV) , where the number of copies of the same gene differs between individuals, in affecting clinical parameters of HIV infection is of interest (Hollox & Hoh, 2014) . In particular, sequence and CNV of the killer immunoglobulin receptor family (KIR) has been shown to be important in control of the progression of HIV (Pelak et al., 2011) , particularly in the context of variation at its ligand HLA-B (Bashirova et al., 2011) . The role of CCL3L1 copy number in HIV infection and progression has been much debated (Cantsilieris & White, 2013) , and most studies that used robust approaches to measure copy number failed to find any association with likelihood of infection or viral load (Gonzalez et al., 2005; Bhattacharya et al., 2009; Field et al., 2009; Urban et al., 2009; Carpenter et al., 2011; Aklillu et al., 2013; Hollox & Hoh, 2014) .
The β-defensins are a family of multifunctional peptides with roles in inflammation and reproduction as well as direct antiviral and antimicrobial effects (Semple & Dorin, 2012; Dorin & Barratt, 2014; Wiens et al., 2014) . In humans, eight β-defensin genes show extensive CNV as a block, with a modal copy number of 4 per diploid genome (Hollox et al., 2008) . This variation is reflected in levels of β-defensin in the serum, at least for human β-defensin 2 (hbd2), encoded by the DEFB4 gene (Jansen et al., 2009 , Jaradat et al., 2013 . Of the eight β-defensin genes, two (DEFB4 and DEFB103 encoding hbd2 and hbd3, respectively) have been shown to encode peptides that have anti-HIV activity in vitro (Chang & Klotman, 2004) . They have also been shown to have chemotactic activity, and hbd3 has been shown to stimulate the type 1 interferon-β response to the viral ligand mimic polyI:C (Semple et al., 2015) .
Some studies have suggested a relationship between low β-defensin copy number and increased HIV susceptibility (Milanese et al., 2009 , Mehlotra et al., 2012 . However, these studies had small sample sizes and used often unreliable quantitative polymerase chain reaction (PCR) assays, increasing the potential false-positive rate (Mehlotra et al., 2016) . Other work, using a more robust triplex paralogue ratio test (PRT) approach to measure β-defensin copy number and much larger sample sizes, examined the association of β-defensin CNV with viral load before initiation of highlyactive antiretroviral therapy (HAART), and immune reconstitution following initiation of antiretroviral therapy (Hardwick et al., 2012) . This study used a cohort of Ethiopian and Tanzanian patients who were naïve to antiretrovirals and were at a late stage of HIV infection (CD4+ T-cell count <200 cells/mm 3 ), and found an association of higher copy number with higher viral load immediately prior to HAART and with poorer immune reconstitution. This was in contrast to functional studies that together implied an anti-HIV effect of β-defensins (Quiñones-Mateu et al., 2003; Sun et al., 2005 Sun et al., , 2006 , but some studies used high concentrations of β-defensins in vitro, often in the absence of serum. At in vivo levels, under more realistic assay conditions, the predominant effect of β-defensins at the site of infection may be to act as a chemokine recruiting Th17 cells (Ghannam et al., 2011) , which are particularly susceptible to HIV infection (Gosselin et al., 2010 , Alvarez et al., 2013 .
Given these results, further exploration of the role of the β-defensin CNV in clinical parameters relating to HIV infection was warranted. The International AIDS Vaccine Initiative Protocol C (IAVI) is a prospective cohort study that follows HIV progression and transmission longitudinally since seroconversion in a cohort of sub-Saharan Africans from several centres across south and east Africa. The Swiss HIV Cohort Study (SHCS) is a longitudinal study of adult HIV patients recruited from across Switzerland where clinical and laboratory parameters are followed at 6-month intervals. Both differ from the initial study in that the viral load at set point (spVL) is the primary clinical variable tested for genetic association, rather than VL immediately prior to HAART or response to HAART (follow-up of CD4 count). This is in common with other studies investigating the role of host genetic factors in HIV.
Our aim in this study is to further explore the relationship between β-defensin copy number and HIV infection. We investigate the role of β-defensins in modifying three clinical parameters: HIV susceptibility, HIV VL at set point, and HIV progression. We use a method to type β-defensin copy number that has been extensively validated and is considerably more robust than alternative quantitative PCR methods.
Methods

Ethics and Cohort Details
All participants from the IAVI and SHCS cohorts were HIV-1-infected adults. The IAVI cohort comprised recent HIV-1 seroconverters (SCs) enrolled from Kenya, Rwanda, Uganda, and Zambia between 2006 and 2011, under a uniform study protocol sponsored by the IAVI (Price et al., 2011; Amornkul et al., 2013) . The procedures for written informed consent and multidisciplinary research activities were approved by institutional review boards at all clinical research centres and participating institutions. The SHCS was approved by the local ethics committees of all participating centres, and written informed consent was obtained from the participants. The study has enrolled more than 18,000 HIV-infected individuals to date. Sociodemographic and behavioural data are recorded at entry to the study, in particular year of birth, gender, and the date of the last negative HIV test. Laboratory and clinical data, including viral load and CD4+ T-cell count, are obtained at each semi-annual follow-up visit.
β-Defensin CNV Typing
We used a triplex PRT for determining diploid copy number at the β-defensin region (Armour et al., 2007; Aldhous et al., 2010; Fode et al., 2011) . Briefly, PRT is a form of quantitative PCR where test and reference loci are amplified by the same primer pair minimising the differences in amplification kinetics between them. At the endpoint of PCR, the test and reference products can be distinguished and quantified using capillary electrophoresis. With each PCR, six positive controls of known copy number are used to generate a calibration curve and normalise across experiments. In this study, we used the same six samples throughout, which were the same as used in previous studies, ensuring comparability of data. Data for each cohort were visualised using scatterplots of results from individual assays and histograms of the results from the three assays combined. Numbers of individuals of each copy number are shown, with the frequency of that copy number shown in parentheses.
Data Analysis
The spVL was determined previously as the geometric mean of the eligible log10 viral load measurements in each individual (Fellay et al., 2007) . Regression models were constructed using the generalised linear model framework in IBM SPSS Statistics v22. Normalised raw PRT copy number (i.e., not rounded or binned) was used as a measure of real underlying copy number of the locus in logistic regression, linear regression, and Cox proportional hazards regression models, as was done previously (Wain et al., 2014) . Covariates in the models were sex, age, and principal components of genetic variation, derived from genome-wide single-nucleotide polymorphisms (SNP) genotypes. We repeated all analyses with rounded (binned) integer copy number estimates and maximum-likelihood estimates of the integer copy number (Aldhous et al., 2010) with no significant change in results.
Integer copy number values presented in Table 1 are from maximum-likelihood analysis calls, consistent with previous publications (Fode et al., 2011; Hardwick et al., 2011; Wain et al., 2014) .
Results and Discussion
We typed 387 samples from the IAVI cohort for β-defensin genomic copy number using a previously published triplex paralogue ratio test (PRT). Clear evidence of clustering of raw copy numbers was observed; however, for the IAVI cohort, there was some considerable overlap between copy numbers 3 and 4 ( Supplementary Figure 1) , which may to be due to heterogeneity between the multiple locations of sample collection and extraction. Of the 387 samples, 302 had matching spVL data ( Table 2) . Analysis of the copy number distribution at the nine different sampling sites showed a modal copy number of 4 or 5, ranging between 1 and 9 (Table 1) , broadly consistent with previous data. There is a notable difference in frequency of the 6 copy individuals between the current sample from Lusaka and a previous sample of individuals with unknown HIV status, but this is most likely due to a sampling artefact. Using the weighted mean raw copy number values generated by PRT, we tested for association with log(spVL) using a generalised linear model, with sex, age, and the first three principal components of genomewide SNP genotype data as covariates. We found no association with β-defensin genomic copy number (β = 0.007, 95% CI -0.064 to 0.077, P = 0.853; Table 3 ).
We then typed 3155 individuals for β-defensin genomic copy number from the Swiss HIV cohort using triplex PRT. Clustering of raw copy numbers was equivalent to previous studies (Supplementary Figure 1, Hardwick et al., 2011; Hardwick et al., 2012; Wain et al., 2014) . Analysis of the copy number distribution showed a modal copy number of 4, ranging between 1 and 9 (Table 1) , consistent with previous data. Of these samples, 1525 had matching spVL data (Table 2 ). Using the weighted mean raw copy number values generated by the PRT, we tested for association with spVL using a generalised linear model, with sex, age, and the first two principal components of genome-wide SNP genotype data as covariates. We found no association with β-defensin genomic copy number (β = -0.02, 95% CI -0.06 to 0.021, P = 0.335; Table 4 ).
Previous work had also analysed the association of VL with the β-defensin copy number by dividing the copy number distribution, ranging from 1 to 9, into two discrete categories, 4 or more copies and fewer than 4 copies. This has the potential to increase power, as a linear response to copy number is not assumed. However, using the same covariates as above, neither the SHCS cohort nor the IAVI cohort showed any association (reference category copy number <4, β = -0.015, 95% CI -0.117 to 0.087, P = 0.773 for the SHCS cohort; β = -0.22, 95% CI -0.567 to 0.127, P = 0.214 for the IAVI cohort).
In both cohorts, we found a highly significant association between males and higher spVL values (Tables 3 and  4) , as has been observed previously (Farzadegan et al., 1998; Junghans et al., 1999; Donnelly et al., 2005) . We also found a significant association with the first principal component of genetic variation in the IAVI cohort but not the SHCS cohort (Tables 3 and 4 ). However, it should be noted that the first principal component of genetic variation is not comparable between the studies, and in the IAVI dataset, it will measure a greater degree of variation across the geographically distinct populations sampled, reflecting both genetic and confounding environmental differences between these populations.
An alternative clinical variable that shows evidence of association with host genetic variation is the rate of progression of HIV from seroconversion to a CD4+ T-cell level of <350 cells/mm 3 or to treatment start. Progression data for 229 individuals from the SHCS were available. Using a Cox regression model, we found no statistically significant association with β-defensin copy number (Exp(B) = 1.122, P = 0.154; Table 5 ). Similar progression data for the IAVI cohort was available for 301 individuals, and, again, we found no statistically significant association with β-defensin copy number (Exp(B) = 0.985, P = 0.829; Table 6 ). Both analyses found a statistically significant relationship with initial viral load, as expected, and a lower hazard ratio for women relative to men, reflecting a slower rate of progression in women, as previously observed (Jarrin et al., 2008) . We finally investigated whether there was evidence of association of β-defensin copy number and the risk of acquiring HIV by constructing an analysis in which the cases are from the SHCS are compared with individuals of European descent of unknown HIV status previously typed as part of other studies. We used 1156 individuals from a population cohort from Nottingham, UK, and 695 individuals from Leicester, UK (Wain et al., 2014) , combined with 183 UK individuals from the European Collection of Authenticated Cell Cultures Human Random Controls cohort . These individuals were of unknown HIV status, and are treated as controls. Using logistic regression with case/control as the binary outcome variable, we found no association with β-defensin copy number (Figure 1 , β = 0.009, 95% CI -0.042 to 0.061, P = 0.725).
Taken together, we find no evidence for association of with HIV susceptibility or spVL. We also find no evidence of a strong effect on the HIV progression rate, although it should be noted that the small sample size makes it unlikely that we could detect a small-or medium-sized effect. Recent evidence has shown that common single-nucleotide variation at the HLA locus and CCR5 is responsible for 25% of variability in spVL and that further studies should be focused on other classes of variation, such as rare SNVs and CNVs (McLaren et al., 2015) . With increasing affordability of short read sequencing, genome-wide analysis of CNVs, including complex multiallelic CNVs such as the β-defensin locus, is becoming possible on larger numbers of sequences and ultimately direct genome-wide typing of CNVs in large cohorts will reveal the contribution to host variation in HIV response and response to other infectious diseases.
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